CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
Rhea-AI Summary
CorMedix (Nasdaq: CRMD) will report first quarter 2026 financial results for the period ended March 31, 2026, before the market opens on Thursday, May 14, 2026. The company will host a corporate update conference call at 8:30am Eastern Time with domestic and international dial-in numbers and a webcast.
Positive
- None.
Negative
- None.
News Market Reaction – CRMD
In the May 5 session, CRMD declined 2.15%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Earnings date notice | Neutral | +1.1% | Scheduled Q4 and full-year 2025 earnings release with 8:30am ET call details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The prior earnings date announcement saw a modest positive move of 1.12%, similar to today’s pre-announcement uptick.
Recent CRMD news featured strong 2025 financial results, guidance, and positive Phase III data for REZZAYO. Notably, Q4 2025 net revenue was $128.6M with pro forma 2025 revenue of $401.3M, while a March earnings date notice preceded full-year results and a 1.12% gain. The current May 14, 2026 earnings-date announcement continues a pattern of scheduled updates followed by detailed financial and clinical disclosures.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the first quarter ended March 31, 2026, before the market opens on Thursday, May 14, 2026, and will host a corporate update conference call at 8:30am Eastern Time.
| Thursday, May 14th @ 8:30am ET | |
| Domestic: | 1-844-676-2922 |
| International: | 1-412-634-6840 |
| Webcast: | Webcast Link |
About CorMedix
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases in the United States. CorMedix is focused on selling and marketing products in institutional settings of care in the US and has field based medical and commercial infrastructure deployed in hospitals, clinics and infusion centers. For more information visit: www.cormedix.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
